3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
46
Stomach Neoplasms
10
Neoplasms
10
Colorectal Neoplasms
8
Neoplasm Metastasis
7
HER2-positive Breast Cancer
7
Esophageal Neoplasms
5
Triple Negative Breast Neoplasms
4
Salivary Gland Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Adenocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Meningeal Neoplasms
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Solid Tumor, Adult
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Interventions
pembrolizumab
8
Nivolumab
6
Ipilimumab
6
cemiplimab
4
aldesleukin
3
Interleukin-2
3
Blood Specimen Collection
3
fludarabine
2
Specimen Handling
2
HhAntag691
2
Cyclophosphamide
2
Biopsy
2
trametinib
1
spartalizumab
1
sonidegib
1
pertuzumab
1
lifileucel
1
four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate)
1
fludarabine phosphate
1
dabrafenib
1
brodalumab
1
atezolizumab
1
Vitamin A
1
Trastuzumab
1
Tissue Banks
1
Surgical Procedures, Operative
1
Standard of Care
1
Second Harmonic Generation Microscopy
1
Resistance Training
1
Red Light
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Skin Neoplasms
×
Trastuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled